TSC/mTORC1 mediates mTORC2/AKT1 signaling in c-MYC–induced murine hepatocarcinogenesis via centromere protein M
Open Access
- 26 September 2024
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 134 (22)
Abstract
Activated mTORC2/AKT signaling plays a role in hepatocellular carcinoma (HCC). Research has shown that TSC/mTORC1 and FOXO1 are distinct downstream effectors of AKT signaling in liver regeneration and metabolism. However, the mechanisms by which these pathways mediate mTORC2/AKT activation in HCC are not yet fully understood. Amplification and activation of c-MYC are key molecular events in HCC. In this study, we explored the roles of tuberous sclerosis complex/mTORC1 (TSC/mTORC1) and FOXO1 as downstream effectors of mTORC2/AKT1 in c-MYC–induced hepatocarcinogenesis. Using various genetic approaches in mice, we found that manipulating the FOXO pathway had a minimal effect on c-MYC–induced HCC. In contrast, loss of mTORC2 inhibited c-MYC–induced HCC, an effect that was completely reversed by ablation of TSC2, which activated mTORC1. Additionally, we discovered that p70/RPS6 and 4EBP1/eIF4E acted downstream of mTORC1, regulating distinct molecular pathways. Notably, the 4EBP1/eIF4E cascade is crucial for cell proliferation and glycolysis in c-MYC–induced HCC. We also identified centromere protein M (CENPM) as a downstream target of the TSC2/mTORC1 pathway in c-MYC–driven hepatocarcinogenesis, and its ablation entirely inhibited c-MYC–dependent HCC formation. Our findings demonstrate that the TSC/mTORC1/CENPM pathway, rather than the FOXO cascade, is the primary signaling pathway regulating c-MYC–driven hepatocarcinogenesis. Targeting CENPM holds therapeutic potential for treating c-MYC–driven HCC.Keywords
Funding Information
- National Institutes of Health (R01CA239251,R01CA250227,P30DK026743,U54GM138062,P20GM103466,U54MD007601,U54HG013243,P20GM139753)
- National Natural Science Foundation of China (82372660)
- Sichuan Science and Technology Program (2024NSFSC0058)
- Clinical Research Fund (2024HXFH030)
- Natural Science Basic Research Program of Shaanxi (2024JC-YBQN-0832)
This publication has 36 references indexed in Scilit:
- Hydrodynamic Transfection for Generation of Novel Mouse Models for Liver Cancer ResearchThe American Journal of Pathology, 2014
- Insulin regulates liver metabolism in vivo in the absence of hepatic Akt and Foxo1Nature Medicine, 2012
- Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trialThe Lancet Oncology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaNew England Journal of Medicine, 2008
- Ras, PI(3)K and mTOR signalling controls tumour cell growthNature, 2006
- Somatic integration of an oncogene-harboring Sleeping Beauty transposon models liver tumor development in the mouseProceedings of the National Academy of Sciences, 2005
- MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancerNature, 2004
- Rictor, a Novel Binding Partner of mTOR, Defines a Rapamycin-Insensitive and Raptor-Independent Pathway that Regulates the CytoskeletonCurrent Biology, 2004
- TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signallingNature Cell Biology, 2002
- Raptor, a Binding Partner of Target of Rapamycin (TOR), Mediates TOR ActionCell, 2002